{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:37:36Z","timestamp":1648906656507},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s11899-008-0029-3","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T07:18:34Z","timestamp":1224055114000},"page":"204-209","source":"Crossref","is-referenced-by-count":2,"title":["Mantle cell lymphoma: Frontline and salvage therapy"],"prefix":"10.1007","volume":"3","author":[{"given":"Jorge E.","family":"Romaguera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"issue":"Suppl2","key":"29_CR1","first-page":"S60","volume":"11","author":"P. Meusers","year":"1997","unstructured":"Meusers P, Hense J, Brittinger G: Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997, 11(Suppl 2):S60\u2013S64.","journal-title":"Leukemia"},{"key":"29_CR2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2559.2000.00895.x","volume":"36","author":"N.L. Harris","year":"2000","unstructured":"Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000, 36:69\u201386.","journal-title":"Histopathology"},{"key":"29_CR3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","volume":"7","author":"P. Jares","year":"2007","unstructured":"Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750\u2013762.","journal-title":"Nat Rev Cancer"},{"key":"29_CR4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E. Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558\u2013565.","journal-title":"Blood"},{"key":"29_CR5","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"J.E. Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013\u20137023.","journal-title":"J Clin Oncol"},{"key":"29_CR6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M. Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, et al.: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005, 131:29\u201338.","journal-title":"Br J Haematol"},{"key":"29_CR7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A. Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185\u2013197.","journal-title":"Cancer Cell"},{"key":"29_CR8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O. Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, et al.: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111:2385\u20132387.","journal-title":"Blood"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G. Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"29_CR10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H. Schultz","year":"2007","unstructured":"Schultz H, Bohlius JF, Trelle S, et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706\u2013714.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl2","key":"29_CR11","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","volume":"8","author":"L.E. Fayad","year":"2007","unstructured":"Fayad LE, Thomas DA, Romaguera JE: Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007, 8(Suppl 2):S57\u2013S62.","journal-title":"Clin Lymphoma Myeloma"},{"key":"29_CR12","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","volume":"17","author":"B.S. Kahl","year":"2006","unstructured":"Kahl, BS, Longo WL, Eickhoff JC, et al.: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006, 17:1418\u20131423.","journal-title":"Ann Oncol"},{"key":"29_CR13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F. Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587\u2013593","journal-title":"Leukemia"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","volume":"16","author":"A.K. Ganti","year":"2005","unstructured":"Ganti AK, Bierman PJ, Lynch JC, et al.: Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005, 16:618\u2013624.","journal-title":"Ann Oncol"},{"key":"29_CR15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","volume":"102","author":"A.M. Gianni","year":"2003","unstructured":"Gianni AM, Magni M, Martelli M, et al.: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749\u2013755.","journal-title":"Blood"},{"key":"29_CR16","doi-asserted-by":"crossref","first-page":"386a","DOI":"10.1182\/blood.V110.11.1281.1281","volume":"110","author":"N.S. Andersen","year":"2007","unstructured":"Andersen NS, Pedersen LB, Laurell A, et al.: Successful preemotive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma [abstract 1281]. Blood 2007, 110:386a.","journal-title":"Blood"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M. Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677\u20132684.","journal-title":"Blood"},{"key":"29_CR18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","volume":"98","author":"I.F. Khouri","year":"2003","unstructured":"Khouri IF, Saliba RM, Okoroji GJ, et al.: Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003, 98:2630\u20132635.","journal-title":"Cancer"},{"key":"29_CR19","first-page":"425","volume":"91","author":"S. DeGuibert","year":"2006","unstructured":"DeGuibert S, Jaccard A, Bernard M, et al.: Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006, 91:425\u2013426.","journal-title":"Haematologica"},{"key":"29_CR20","doi-asserted-by":"crossref","first-page":"LB1","DOI":"10.1182\/blood-2007-04-084509","volume":"110","author":"C.H. Geisler","year":"2007","unstructured":"Geisler CH, Elonen E, Kolstad A, et al.: Mantle cell lymphoma can be cured by intensive immunochemotherapy with in-vivo purged stem-cell support; final report of the Nordic Lymphoma Group MCL2 Study [abstract 1]. Blood 2007, 110:LB1.","journal-title":"Blood"},{"key":"29_CR21","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","volume":"21","author":"I.F. Khouri","year":"2003","unstructured":"Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407\u20134412.","journal-title":"J Clin Oncol"},{"key":"29_CR22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M. Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, et al.: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705\u2013711.","journal-title":"J Clin Oncol"},{"key":"29_CR23","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R. Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003\u20134008.","journal-title":"Blood"},{"key":"29_CR24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C. Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S, et al.: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271\u20132278.","journal-title":"Blood"},{"key":"29_CR25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2000.18.4.773","volume":"18","author":"P.I. Zinzani","year":"2000","unstructured":"Zinzani PI, Magagnoli M, Moretti L, et al.: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000, 18:773\u2013779.","journal-title":"J Clin Oncol"},{"key":"29_CR26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","volume":"16","author":"D. Decaudin","year":"1998","unstructured":"Decaudin D, Bosq J, Munck JN, et al.: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579\u2013583.","journal-title":"J Clin Oncol"},{"key":"29_CR27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","volume":"42","author":"B.J. Cohen","year":"2001","unstructured":"Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015\u20131022.","journal-title":"Leuk Lymphoma"},{"key":"29_CR28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","volume":"17","author":"J.M. Foran","year":"1999","unstructured":"Foran JM, Rohatiner AZ, Coiffier B, et al.: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m\u2019s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999, 17:546\u2013553.","journal-title":"J Clin Oncol"},{"key":"29_CR29","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Von Gruenhagen U, Niederle N, et al.: Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas \u2014 first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract 385]. Blood 2007, 110.","DOI":"10.1182\/blood.V110.11.385.385"},{"key":"29_CR30","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E. Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Alvire C, Loberiza FR, et al.: Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793\u2013800.","journal-title":"Br J Haematol"},{"key":"29_CR31","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","volume":"99","author":"A.K. Gopal","year":"2002","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158\u20133162.","journal-title":"Blood"},{"key":"29_CR32","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R. Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064\u20133071.","journal-title":"Blood"},{"key":"29_CR33","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"R.I. Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"29_CR34","doi-asserted-by":"crossref","unstructured":"Drach J, Kaufmann H, Pichelmayer O, et al.: Bortezomib, rituximab, and dexamethasone (BORID) as salvage treatment in relapsed\/refractory mantle cell lymphoma: sustained disease control in patients achieving a complete remission [abstract 2578]. Blood 2007, 110.","DOI":"10.1182\/blood.V110.11.2578.2578"},{"key":"29_CR35","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","volume":"104","author":"H. Kaufmann","year":"2004","unstructured":"Kaufmann H, Raderer M, W\u00f6hrer S, et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma. Blood 2004, 104:2269\u20132271.","journal-title":"Blood"},{"key":"29_CR36","doi-asserted-by":"crossref","unstructured":"Wang M, Fayad LE, Hagemeister FB, et al.: Lenalidomide (Len) in combination with rituximab (R) demonstrated early evidence of efficacy in a phase I\/II study in relapsed\/refractory mantle cell lymphoma (MCL) [abstract 2562]. Blood 2007, 110.","DOI":"10.1182\/blood.V110.11.2562.2562"},{"key":"29_CR37","doi-asserted-by":"crossref","unstructured":"Hess G, Romaguera JE, Verhof G, et al.: Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator\u2019s choice therapy [abstract 8513]. ASCO Proc 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.8513"},{"key":"29_CR38","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","volume":"48","author":"J. Rodriguez","year":"2007","unstructured":"Rodriguez J, Gutierrez A, Palacios A, et al.: Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007, 48:2172\u20132178.","journal-title":"Leuk Lymphoma"},{"key":"29_CR39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/10428190701361216","volume":"48","author":"T. Robak","year":"2007","unstructured":"Robak T, Lech-Maranda E, Janus A, et al.: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 2007, 48:1092\u20131101.","journal-title":"Leuk Lymphoma"},{"key":"29_CR40","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"M.J. Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:3383\u20133389.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-008-0029-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-008-0029-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:10:35Z","timestamp":1589001035000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-008-0029-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s11899-008-0029-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}